Amarin says payers response on new Vascepa indication ‘very positive’

In a statement to the Fly, Amarin (AMRN) said: “We do not generally comment on changes in specific plans, as the access landscape can be very fluid. With that said, Vascepa’s new FDA-approved cardiovascular risk reduction indication has received a significant amount of attention with payers. While we are early in the process of our discussions with payers regarding the new indication, the response has been very positive. Vascepa is covered by the vast majority of Commercial and Medicare Part D payers, and we anticipate that patient access will continue to improve overall as payers adapt to the new indication.”